Search

Displaying results 5681 - 5690 of 7452 in total
  1. Drug

    QazCovid-in

    go.drugbank.com/drugs/DB16441
    Investigational

    The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems[L30628].

  2. Drug

    Devafidugene civaparvovec

    go.drugbank.com/drugs/DB16790
    Investigational

    Developed by Sangamo Therapeutics, Inc., devafidugene civaparvovec is being investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46716]

  3. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    It is being investigated for the treatment of melanoma.

  4. Drug

    NGN-401

    go.drugbank.com/drugs/DB18594
    Investigational

    Developed by Neurogene Inc., it is being investigated for the treatment of Rett syndrome.

  5. Drug

    WNY0824

    go.drugbank.com/drugs/DB23606
    Experimental

    WNY0824 is a preclinical small molecule drug being investigated for the treatment of Castration-Resistant Prostrate Cancer (CRPC).

  6. Drug

    PHB-050

    go.drugbank.com/drugs/DB32061
    Experimental

    [L54988] It is under investigation for the treatment of multiple atopic diseases, including food allergies, asthma, and atopic dermatitis.[L54988]

  7. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways. It is used to treat Parkinson's Disease, Alzheimer's Disease, Retinal Disorders and other neurologic Disorders.

  8. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect

  9. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

  10. Drug

    SOR-C13

    go.drugbank.com/drugs/DB15366
    Investigational

    SOR-C13 is under investigation in clinical trial NCT01578564 (Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel).